SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is trending downwards as investors react to Michael Burry's reported short position and concerns about the stock's high valuation despite strong earnings and raised guidance; the community is debating whether this is a buying opportunity or a sign of an AI bubble, while also scrutinizing CEO Alex Karp's response to the short sellers.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE CRYPTO is trending as the community rallies around the OG meme, emphasizing retail unity and a return to the values that built the internet. Discussions focus on the power of community, conviction, and the potential for a cultural reset in the crypto space. Believers are expressing enthusiasm and long-term commitment, anticipating a potential moonshot.

$WAGMI is a community-driven meme token built on the Solana blockchain, designed to bring positivity, unity, and humor into the crypto space. The project encourages community engagement through memes, social interaction, and token-based activities. It leverages Solana’s fast and low-cost infrastructure to allow for smooth on-chain interactions, such as token transfers, community games, and NFT integration. The goal is to foster a fun, inclusive ecosystem where holders feel they are part of a larger movement – "We Are Gonna Make It."

WAGMI

WAGMI is trending as the community rallies around the "We're All Gonna Make It" mantra, despite some recent price volatility. Discussions highlight community strength and support for related tokens like $SOL, with some users emphasizing a long-term, bullish outlook. The community is actively promoting its vision and encouraging others to join.

Welcome to SLAP – The Only Coin That Slaps Harder Than Your Moms  Tired of coins that claim they SLAP but are nothing but limp wrists? SLAP is here to SLAP some sense into the crypto space.  Founded by the Flutter of Five Fingers and powered by the Prancing of the Pried Palm, SLAP isn’t just another coin—it’s an attitude.  We’re not here to talk roadmaps, utility, or world peace. We’re here to SLAP charts, SLAP the haters, and SLAP our way to the top. No VC suits, no corporate nonsense—just raw, unfiltered internet culture with a side of “did we just do that?  ”So load your wallet, mute your financial advisor, and get ready to ride the most unhinged meme rocket. Open up your hands, and start swingin'. You never know what you could hit.  SLAP: It’s not a coin. It’s a lifestyle.

Slap

$SLAP is trending amidst community enthusiasm, with many highlighting the project's strong community and potential. Active discussions revolve around staking and IRL partnerships, as well as positive sentiment towards the team's efforts. The crypto community is rallying behind the token, emphasizing a shared vision and collective success.

Hertz Global Holdings, Inc. engages in the vehicle rental business through the Hertz, Dollar, and Thrifty brands. It operates under the Americas Rental Car (RAC) and International Rental Car (RAC) segments. The Americas RAC segment focuses on operations in the United States, Canada, Latin America, and the Caribbean. The International RAC segment includes the provision of rental and sales of vehicles and value-added services in other locations. The company was founded in 1918 and is headquartered in Estero, FL.

Hertz Global Holdings Inc. - Ordinary Shares (New)

HTZ is trending due to positive earnings news and potential short squeeze, sparking bullish sentiment. The community is discussing whether HTZ could become the next meme stock with high short interest and a possible squeeze fueled by retail investors. Some are comparing the stock's turnaround to Carvana's and anticipating a climb to double digits.

Uber Technologies, Inc. is a technology platform, which engages in the development and operation of technology applications, networks, and product to power movement from point A to point B. The firm offers ride services and merchants delivery service providers for meal preparation, grocery, and other delivery services. It operates through the following segments: Mobility, Delivery, and Freight. The Mobility segment refers to products that connect consumers with Mobility Drivers who provide rides in a variety of vehicles, such as cars, auto rickshaws, motorbikes, minibuses, or taxis. The Delivery segment offers consumers the chance to search for and discover local restaurants, order a meal, and either pick-up at the restaurant or have the meal delivered. The Freight segment focuses on connecting Carriers with Shippers on its platform, and gives Carriers upfront, transparent pricing, and the ability to book a shipment. The company was founded by Oscar Salazar Gaitan, Travis Kalanick, and Garrett Camp in 2009 and is headquartered in San Francisco, CA.

Uber Technologies Inc

Uber is trending amidst strong Q3 earnings results, with community chatter focusing on revenue and bookings growth, and potential for future gains. Despite positive reports, some express concern over operating profit margins and overall market conditions impacting the stock's performance. Discussions also highlight Uber's moves in autonomous vehicles and partnerships as long-term growth catalysts.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is trending due to reports of a potential White House deal to expand Medicare coverage for obesity drugs, which could significantly increase access to their GLP-1 medications. While some investors are excited about the expanded market, others worry about potential price caps and increased competition from Eli Lilly and Pfizer. Community chatter revolves around whether this news will reverse the stock's recent downward trend, with some seeing it as a buying opportunity.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is trending as investors debate its current valuation and future prospects ahead of earnings. Community chatter revolves around recent price drops, potential market manipulation, and the impact of prediction markets on the company's core business. Some are optimistic about a potential earnings beat and long-term growth in the sports betting market, while others express concerns about competition and overall market sentiment.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lilly is trending amid discussions of their oral GLP-1, orforglipron, showing strong results in Phase 3 trials for diabetes, potentially becoming a new standard of care. Community members are also actively monitoring for news regarding potential acquisitions and impacts from political discussions on drug pricing, with varied opinions on the stock's valuation and future growth compared to competitors.

Norwegian Cruise Line Holdings Ltd. engages in the provision of cruise travel services. It offers cruise experiences for travelers with itineraries in Europe, Asia, Australia, New Zealand, South America, Africa, Canada, Bermuda, Caribbean, Alaska and Hawaii. Its brands include Norwegian Cruise Line, Oceania Cruises, and Regent Seven Seas Cruises. The company was founded in 1966 and is headquartered in Miami, FL.

Norwegian Cruise Line Holdings Ltd

Despite a recent price surge, NCLH is trending downwards, influenced by overall market trends and competitor performance; the stock is currently trading below COVID pricing, sparking discussions of oversold conditions and potential buying opportunities. While some community members point to solid earnings and future potential, others express concerns over debt and revenue misses, contributing to the ongoing debate on the stock's valuation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Metsera says Novo Nordisk's new bid for obesity drugmaker is 'superior' to revised Pfizer offer

The clash reflects the shifting landscape for weight loss and diabetes drugs, with Novo Nordisk trailing Eli Lilly as companies like Pfizer race to break in...

<ul class="summary-bullets"><li>Novo’s new proposal values Metsera at about $10 billion while Pfizer’s revised proposal values the company at about $8.1 billion.&nbsp;</li><li>Pfizer now has two business days to negotiate the terms of its agreement with Metsera.</li><li>As of date, Novo’s proposal constitutes a superior one to Pfizer’s, Metsera said.&nbsp; &nbsp;</li></ul>Metsera (MTSR) announced on Tuesday that it has received a revised acquisition proposal from Novo Nordisk (NVO) valuing the company at up to $86.20 per share or approximately $10 billion.The new proposal constitutes a superior proposal to its existing merger agreement with Pfizer, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/metsera-receives-amended-proposal-from-novo-nordisk-metsera-declares-novo-nordisk-amended-proposal-superior-302604143.html">noted</a>.<h2 class="st-heading-2">Revised Proposals</h2>Under the revised proposal, Novo Nordisk would pay Metsera $62.20 per Metsera common share in cash, up from $56.50 in the original proposal, immediately after the signing of a definite deal. Metsera would issue non-voting preferred stock to Novo Nordisk, representing 50% of Metsera's share capital in exchange.Following approval from shareholders and regulators, Metsera shareholders will then receive a contingent value right representing up to $24.00 per share in cash, an increase from $22.50 in the initial proposal, contingent upon the completion of certain milestones. Novo will then acquire the remainder of the outstanding shares.Metsera also said that Pfizer revised the terms of its agreement on Monday. Pfizer increased the upfront consideration to $60.00 per share in cash, up from $47.50, and decreased the amount payable under CVR to up to $10.00 per share in cash, down from $22.50, it said. The revised Pfizer proposal values Metsera at up to $70 per share or $8.1 billion.However, Novo’s proposal continues to be a superior one, and Pfizer has two business days to negotiate with Metsera for further adjustments to the terms and conditions of the merger agreement.Metsera said that it would be entitled to terminate its merger agreement with Pfizer if Novo’s proposal continues to be superior. However, at this time, the Pfizer Merger Agreement remains in full effect, it added.<h2 class="st-heading-2">Pfizer Hits Back At Novo Bid</h2>Novo Nordisk first announced on Thursday that it has submitted an unsolicited proposal to acquire Metsera, following Pfizer's agreement to acquire the smaller obesity biopharmaceutical company in September. Pfizer has since filed two lawsuits against the proposal.The lawsuit filed earlier this week against Metsera, its controlling stockholders and Novo Nordisk alleges that Novo Nordisk’s proposal to acquire Metsera constitutes an anticompetitive action by the company to protect its dominant market position in GLP-1 drugs by capturing and killing a nascent American competitor before it gains the support of Pfizer.Pfizer also filed a separate lawsuit last week against Metsera, its board and Novo, asserting claims for breach of contract and fiduciary duty. It has also filed a motion with the Court of Chancery, requesting that the court issue a temporary restraining order to block Metsera from terminating the merger agreement with itself.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>MTSR stock traded 20% higher at the time of writing. On Stocktwits, retail sentiment around Metsera stayed within the ‘extremely bullish’ territory while message volume remained at ‘extremely high’ levels.MTSR stock is up by 175% this year.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/elon-musk-one-trillion-pay-package-gets-thumbs-up-from-baron-capital/cL28hdrR36i">Elon Musk’s $1T Pay Package Gets A Thumbs Up From Baron Capital</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Metsera logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Metsera Gets Revised Bids From Pfizer, Novo Nordisk: Here’s Why It Matters

Metsera said that it would be entitled to terminate its merger agreement with Pfizer if Novo’s proposal continues to be superior.

Equity

Metsera Receives Amended Proposal from Novo Nordisk; Metsera Declares Novo Nordisk Amended Proposal "Superior"

Metsera Receives Amended Proposal from Novo Nordisk; Metsera Declares Novo Nordisk Amended Proposal 'Superior' Metsera Receives Amended Proposal from Novo Nordisk; Metsera Declares Novo Nordisk...

<ul class="summary-bullets"><li>Analysts expect Novo Nordisk’s Q3 revenue to fall 2% to $11.87 billion and earnings per share to drop as competition from Eli Lilly intensifies.</li><li>The report marks CEO Mike Doustdar’s first since taking charge, with investors watching for guidance on restructuring, job cuts, and strategy following a board overhaul.</li><li>The earnings release comes as Pfizer escalates its legal battle over Novo’s $9 billion bid for Metsera, accusing the company of trying to delay competition in the obesity drug market.</li></ul>Novo Nordisk will report its third-quarter (Q3) results on Wednesday, marking its first earnings release under new CEO Mike Doustdar. Analysts expect weaker profits and slower growth amid intensifying competition from Eli Lilly and mounting legal pressure from Pfizer.The company’s U.S.-listed stock fell 0.7% to close at $49.11 on Monday.<h2 class="st-heading-2">Analysts Expect Softer Quarter</h2>According to Koyfin estimates, analysts expect revenue of $11.87 billion, down 2% year-on-year. EBITDA is projected at $5.28 billion, a 13% decline, while EBIT is forecast to drop 26% to $3.92 billion. GAAP earnings per share (EPS) is seen at $0.70, compared with $0.94 a year earlier.BMO Capital Markets analyst Evan Seigerman said investors will be looking for signs of how Novo plans to get past restructuring and reignite obesity growth, after multiple guidance cuts this year, according to a Reuters&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/business/healthcare-pharmaceuticals/novo-nordisk-ceo-faces-baptism-fire-amid-board-shakeup-pfizer-fight-2025-11-04/">report</a>.&nbsp;Jefferies analyst Michael Leuchten noted that Novo remains heavily dependent on semaglutide, the active ingredient in Wegovy and Ozempic, which underpins roughly 60% of future revenues. “It looks like the obesity market in the U.S. is running out of steam, and we don’t fully understand why,” Leuchten said, pointing to underwhelming new-patient starts.<h2 class="st-heading-2">Leadership Transition And Legal Uncertainty</h2>The report will also be the first under CEO Mike Doustdar, who took over in August after the Novo Nordisk Foundation, the company’s controlling shareholder, overhauled the board, replacing six independent directors. Former CEO Lars Rebien Sorensen is set to return as chairman following the Nov. 14 shareholder meeting.Paul Major, healthcare portfolio manager at Bellevue Asset Management, said the tone Doustdar sets on the company’s future strategy will be a point of focus, adding that investors are watching for alignment between management and the Foundation on Novo’s turnaround plan.<h2 class="st-heading-2">Pfizer Legal Dispute Adds Pressure</h2>The quarter also comes as Pfizer escalates its legal challenge over Novo’s $9 billion rival bid for Metsera, a U.S. biotech developing next-generation obesity drugs. Pfizer alleged that the Danish drugmaker structured the deal to delay competition and preserve market share for Wegovy and Ozempic.Novo has denied the claims, calling them “absurd” and arguing that it would accelerate Metsera’s commercialization if the claims were successful. The case will be heard on Tuesday.TD Cowen analyst Michael Nedelcovych said he will watch for any insights on the Metsera bid and whether Doustdar signals an appetite for further acquisitions.<h2 class="st-heading-2">Stocktwits Bulls View Novo’s Dip As A Buying Opportunity</h2>On Stocktwits, retail sentiment for both Novo Nordisk and Pfizer was ‘bullish’ amid ‘ high’ message volumes.One user commented that Novo Nordisk’s aggressive $6.5 billion bid for Metsera made it the biggest risk-taker in the dispute with Pfizer, adding that Metsera stood to benefit either way, while Pfizer faced litigation setbacks.<stembedurl>https://stocktwits.com/dyrtydave/message/634800076</stembedurl>Another said investors were overreacting to Novo’s share decline, describing it as a strong global company expanding its pipeline and calling the dip a potential buying opportunity.<stembedurl>https://stocktwits.com/Prit89/message/634764720</stembedurl><a href="https://stocktwits.com/Prit89/message/634764720">Novo Nordisk’s U.S.-listed stock</a> has declined 42% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a Novo Nordisk logo is displayed on a smartphone with stock market percentages in the background. (Photo Illustration by Omar Marques/SOPA Images/LightRocket via Getty Images)

Novo Nordisk Q3 Preview: Analysts See Profit Drop As Obesity Market Cools, Pfizer Tensions Rise

Analysts expect Novo Nordisk’s Q3 revenue to fall 2% to $11.87 billion and earnings per share to drop as competition from Eli Lilly intensifies.

Pfizer plays hardball in weight-loss drug fight

Pfizer has filed two lawsuits to block Novo Nordisk's $9bn bid to buy Metsera...

<ul class="summary-bullets"><li>Revenue rose 49% year-over-year to nearly $600 million, while net income reached $15.8 million and adjusted EBITDA climbed 53% to $78.4 million.</li><li>Subscriber count grew 21% to almost 2.5 million, with monthly online revenue per subscriber up 19% to $80.</li><li>On Stocktwits, retail sentiment was ‘extremely bullish,’ with users predicting the stock could climb toward $50 once Novo Nordisk partnership talks conclude.</li></ul>Shares of Hims &amp; Hers Health rose about 5% in after-hours trading on Monday after the company reported another quarter of strong growth and said it’s in talks with Novo Nordisk to bring&nbsp;weight-loss drug Wegovy to its platform.<h2 class="st-heading-2">Revenue And Subscriber Growth Remain Strong</h2>Revenue rose 49% from a year earlier to $599 million as strength continued across the company’s weight-loss and wellness businesses. Net income was $15.8 million, versus $75.6 million a year ago, which had reflected a one-time tax benefit. Adjusted EBITDA increased 53% to $78.4 million.Hims &amp; Hers now has nearly 2.5 million subscribers, up 21% from a year earlier, and monthly revenue per subscriber has also risen 19% to $80. Cash from operations soared to $149 million, while free cash flow for the quarter remained stable at $79 million.Gross margin fell to 74%, from 79% a year earlier, mainly due to changes in shipping cadence and higher production costs related to Hims &amp; Hers’ growing weight-loss portfolio.<h2 class="st-heading-2">Talks With Novo Nordisk</h2>The company said it’s in active talks with Novo Nordisk to make Wegovy injections and an eventual oral formulation available on its platform once they have prescribing approval. No agreement has been reached, and the company said that a deal is not guaranteed.The company said during the earnings call that it expects to bring in over $725 million in weight-loss revenue this year, and that it’s spending money to build new sterile compounding and fulfillment centers to keep up with the surge in demand.<h2 class="st-heading-2">Outlook For 2025</h2>Hims &amp; Hers narrowed its 2025 revenue forecast to a range of $2.335 billion to $2.355 billion, slightly above its previous estimate of $2.3 billion to $2.4 billion. It now expects adjusted EBITDA between $307 million and $317 million, compared with the earlier range of $295 million to $335 million.For the fourth quarter, the company expects revenue of $605 million to $625 million and adjusted EBITDA of $55 million to $65 million. The company said near-term margins will be affected by ongoing investments in its compounding operations and by price adjustments to GLP-1 drugs, though it expects conditions to improve next year as volumes continue to rise.<h2 class="st-heading-2">Stocktwits Traders Bet On Further Gains</h2>On Stocktwits, retail sentiment for Hims was ‘extremely bullish’ amid a 1,734% surge in 24-hour message volume.<figure class="image"><img style="aspect-ratio:968/135;" src="https://news.stocktwits-cdn.com/hims_ss_jpg_d349536f51.webp" alt="hims ss.jpg" width="968" height="135"><figcaption>HIMS sentiment and message volume as of November 3 | Source: Stocktwits</figcaption></figure>One user said they viewed the stock as a solid buy for the next move higher, expecting it to stay above the $30 range.&nbsp;<stembedurl>https://stocktwits.com/Lucy888/message/634788120</stembedurl>Another predicted that shares could climb toward $50 following the company’s strong results and new initiatives. Meanwhile, a third user said the stock could rally sharply once its ongoing discussions with Novo Nordisk are concluded.<stembedurl>https://stocktwits.com/bestest1/message/634776299</stembedurl><stembedurl>https://stocktwits.com/Maximusprofit/message/634778175</stembedurl><a href="https://stocktwits.com/symbol/HIMS">Hims &amp; Hers Health’s stock</a> has risen 84% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a HIMS logo is displayed on a smartphone. (Photo Illustration by Avishek Das/SOPA Images/LightRocket via Getty Images)

Hims & Hers Health Stock Jumps After-Hours As Q3 Growth, Novo Nordisk Talks Fuel Bullish Retail Bets

Revenue rose 49% year-over-year to nearly $600 million, while net income reached $15.8 million and adjusted EBITDA climbed 53% to $78.4 million.

Novo Nordisk Before Q3 Earnings: How Should Investors Play the Stock?

NVO faces slowing Wegovy and Ozempic momentum, pricing risks and fierce competition ahead of Q3 earnings.

Pfizer files second lawsuit against Novo Nordisk, Metsera in bidding war over obesity biotech

The suit escalates a battle between Pfizer and Novo Nordisk over Metsera, whose obesity pipeline could yield new competitors in the weight loss drug market...

<ul class="summary-bullets"><li>The new lawsuit alleges that Novo Nordisk’s proposed transaction violates several laws due to the anticompetitive effects it would have on the GLP-1 drug market.</li><li>It further argues that Metsera’s controlling stockholders, including Validae Health, L.P., and Population Health Partners GP, have conspired with Metsera and Novo Nordisk to further these anticompetitive activities.</li><li>Pfizer added that it intends to seek all appropriate remedies, including injunctive relief, to ensure that Novo Nordisk’s proposed transaction is not permitted to move forward. &nbsp;</li></ul>Pfizer Inc. (PFE) on Monday announced that it has filed a second lawsuit against Metsera, Inc., its controlling stockholders, and Novo Nordisk A/S in the United States District Court for the District of Delaware.The lawsuit alleges that Novo Nordisk’s recent proposal to acquire Metsera constitutes an anticompetitive action by the company to protect its dominant market position in GLP-1 drugs by capturing and killing a nascent American competitor before it gains the support of Pfizer.<h2 class="st-heading-2">What Does The New Lawsuit Say?</h2>The new lawsuit <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20251102755714/en/Pfizer-Files-Federal-Antitrust-Claims-in-Second-Lawsuit-Against-Metsera-its-Controlling-Stockholders-and-Novo-Nordisk">alleges</a> that Novo Nordisk’s proposed transaction violates several laws because of the anticompetitive effects it would have in the GLP-1 drug markets and negatively impact patients who suffer from obesity, diabetes, and other metabolic conditions. It further argues that Metsera’s controlling stockholders, including Validae Health, L.P., and Population Health Partners GP, have conspired with Metsera and Novo Nordisk to further these anticompetitive activities.Pfizer further added that it intends to seek all appropriate remedies, including injunctive relief, to ensure that Novo Nordisk’s proposed transaction is not permitted to move forward.“Metsera’s and its controlling stockholders’ actions, as well as those of Novo Nordisk, are in clear violation of the antitrust laws. We are confident in the merits of our case and look forward to presenting it to the Court,” the company said.Pfizer also filed a separate lawsuit last week against Metsera, its Board of Directors, and Novo Nordisk in the Delaware Court of Chancery, asserting claims for breach of contract and fiduciary duty. It has also filed a motion with the Court of Chancery requesting that it issue a temporary restraining order to block Metsera from terminating the merger agreement with itself. &nbsp;<h2 class="st-heading-2">What Sparked The Legal Battle?</h2>Danish drugmaker Novo Nordisk (NVO) announced on Thursday that it has submitted an unsolicited proposal to acquire Metsera, Inc. (MTSR), following Pfizer's (PFE) <a href="https://stocktwits.com/news-articles/markets/equity/metsera-stock-surges-pre-market-after-pfizer-confirms-acquisition/chDQNVhR3cy">agreement</a> to acquire the smaller obesity biopharmaceutical company in September.Metsera subsequently gave Pfizer four business days to negotiate potential adjustments to the existing transaction. The company also noted it would be entitled to terminate the Pfizer merger agreement if Novo’s proposal continues to constitute a superior proposal.Pfizer, however, maintains that Novo's offer cannot be considered a superior proposal, given the significant regulatory risk, among other factors.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/MTSR">MTSR stock</a> stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.MTSR stock has more than doubled this year.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/serina-therapeutics-stock-slumps-premarket-after-fda-place-hold-on-application-to-initiate-clinical-trials-for-experimental-therapy/cL2NcnCR3zB">Serina Therapeutics Stock Slumps Pre-Market After FDA Places Hold On Application To Initiate Clinical Trials For Experimental Therapy</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

The Battle For Metsera Acquisition Heats Up As Pfizer Files A Second Lawsuit 

Pfizer filed the lawsuit against Metsera, Inc., its controlling stockholders, and Novo Nordisk A/S, alleging that Novo Nordisk’s recent proposal to acquire Metsera constitutes an anticompetitive action. 

MIKE DAVIS: Foreign weight-loss drugmaker seeks fat profits by gobbling up American upstart

'Something is rotten in the state of Denmark,' as Hamlet said in Shakespeare's time. It was true then, and it's true today.While Senate Democrats are holding our government hostage to their...

Will Robinhood Markets ($HOOD) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Robinhood Markets Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

NVO
Novo Nordisk A/S

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest NVO News

NVONovo Nordisk A/S